All Outputs (47)

CAMERA - complete assessment of elderly patients with cancer: A non-randomised feasibility study (2018)
Journal Article
Jackson, G., Gabe, R., Johnson, M., Date, K., Harman, D., Maraveyas, A., Roy, R., & Lind, M. J. (2019). CAMERA - complete assessment of elderly patients with cancer: A non-randomised feasibility study. Journal of Geriatric Oncology, 10(1), 175-177. https://doi.org/10.1016/j.jgo.2018.07.005

One of the primary risk factors in the development of cancer is older age. The demographic shift to an ageing population has given rise to an increased number of older patients with cancer. The extreme heterogeneity within this population renders app... Read More about CAMERA - complete assessment of elderly patients with cancer: A non-randomised feasibility study.

MicroRNA-31 regulates chemosensitivity in malignant pleural mesothelioma (2017)
Journal Article
Moody, H. L., Lind, M. J., & Maher, S. G. (2017). MicroRNA-31 regulates chemosensitivity in malignant pleural mesothelioma. Molecular Therapy - Nucleic Acids, 8(15 September 2017), 317-329. https://doi.org/10.1016/j.omtn.2017.07.001

Malignant pleural mesothelioma (MPM) is associated with an extremely poor prognosis, and most patients initially are or rapidly become unresponsive to platinum-based chemotherapy. MicroRNA-31 (miR-31) is encoded on a genomic fragile site, 9p21.3, whi... Read More about MicroRNA-31 regulates chemosensitivity in malignant pleural mesothelioma.

EGFR and related therapeutic targets in malignant pleural mesothelioma (2016)
Thesis
Oguh, L. I. (2016). EGFR and related therapeutic targets in malignant pleural mesothelioma. (Thesis). Hull York Medical School, the University of Hull and the University of York. Retrieved from https://hull-repository.worktribe.com/output/4221787

Introduction
Malignant pleural mesothelioma (MPM) is a rare but aggressive disease and the current first line treatment is associated with a survival rate of 40%. There is currently no second line therapy. This study aimed to explore the expression... Read More about EGFR and related therapeutic targets in malignant pleural mesothelioma.

Investigating the role of microRNA-31 as a modulator of chemosensitivity in malignant leural mesothelioma (2016)
Thesis
Moody, H. L. (2016). Investigating the role of microRNA-31 as a modulator of chemosensitivity in malignant leural mesothelioma. (Thesis). Hull York Medical School, the University of Hull and the University of York. Retrieved from https://hull-repository.worktribe.com/output/4219227

Malignant pleural mesothelioma (MPM) is associated with an extremely poor prognosis and the majority of patients are initially or rapidly become unresponsive to platinum-based chemotherapy. MicroRNA-31 (miR-31) is encoded on a genomic fragile site, 9... Read More about Investigating the role of microRNA-31 as a modulator of chemosensitivity in malignant leural mesothelioma.

Arginine deprivation with pegylated Arginine Deiminase in patients with Argininosuccinate Synthetase 1-Deficient Malignant Pleural Mesothelioma: A Randomized Clinical Trial (2016)
Journal Article
Szlosarek, P. W., Steele, J. P., Nolan, L., Gilligan, D., Taylor, P., Spicer, J., Lind, M., Mitra, S., Shamash, J., Phillips, M. M., Luong, P., Payne, S., Hillman, P., Ellis, S., Szyszko, T., Dancey, G., Butcher, L., Beck, S., Avril, N. E., Thomson, J., …Hackshaw, A. (2017). Arginine deprivation with pegylated Arginine Deiminase in patients with Argininosuccinate Synthetase 1-Deficient Malignant Pleural Mesothelioma: A Randomized Clinical Trial. JAMA Oncology, 3(1), 58-66. https://doi.org/10.1001/jamaoncol.2016.3049

Importance: Preclinical studies show that arginine deprivation is synthetically lethal in argininosuccinate synthetase 1 (ASS1)-negative cancers, including mesothelioma. The role of the arginine-lowering agent pegylated arginine deiminase (ADI-PEG20)... Read More about Arginine deprivation with pegylated Arginine Deiminase in patients with Argininosuccinate Synthetase 1-Deficient Malignant Pleural Mesothelioma: A Randomized Clinical Trial.

The effect of emergency presentation on surgery and survival in lung cancer patients in England, 2006–2008 (2015)
Journal Article
Tataru, D., Jack, R. H., Lind, M. J., Møller, H., & Lüchtenborg, M. (2015). The effect of emergency presentation on surgery and survival in lung cancer patients in England, 2006–2008. Cancer epidemiology, 39(4), 612-616. https://doi.org/10.1016/j.canep.2015.04.008

A large proportion of lung cancer patients in England are diagnosed through an emergency route, which is associated with poorer outcomes. Here, we investigated the association between emergency presentation and the odds of undergoing surgical resecti... Read More about The effect of emergency presentation on surgery and survival in lung cancer patients in England, 2006–2008.

Merkel cell carcinoma in East Yorkshire: A case series and literature review of current management (2015)
Journal Article
Jackson, P. C., Wallis, K., Allgar, V., Lind, M. J., & Stanley, P. R. (2015). Merkel cell carcinoma in East Yorkshire: A case series and literature review of current management. Journal of plastic, reconstructive & aesthetic surgery : JPRAS, 68(5), 667-672. https://doi.org/10.1016/j.bjps.2014.12.021

© 2015 British Association of Plastic, Reconstructive and Aesthetic Surgeons. Introduction Merkel cell carcinoma (MCC) is a rare, aggressive neuroendocrine tumour of the skin. The incidence is rising and it is associated with sun exposure and immunos... Read More about Merkel cell carcinoma in East Yorkshire: A case series and literature review of current management.

Clinical response to primary letrozole therapy in elderly patients with early breast cancer : possible role for p53 as a biomarker (2014)
Journal Article
Garimella, V., Hussain, T., Agarwal, V., Radhakrishna, S., Fox, J. N., Kneeshaw, P. J., Long, E. D., Mahapatra, T. K., McManus, P. L., Lind, M. J., Drew, P. J., & Cawkwell, L. (2014). Clinical response to primary letrozole therapy in elderly patients with early breast cancer : possible role for p53 as a biomarker. International journal of surgery, 12(8), 821-826. https://doi.org/10.1016/j.ijsu.2014.06.009

Primary tamoxifen therapy has been widely used to treat elderly women with ER-positive breast cancer in the past. Aromatase inhibitors may be more beneficial than tamoxifen when used as primary endocrine therapy in elderly patients. We aimed to retro... Read More about Clinical response to primary letrozole therapy in elderly patients with early breast cancer : possible role for p53 as a biomarker.

Survival of patients with small cell lung cancer undergoing lung resection in England, 1998–2009 (2013)
Journal Article
Lüchtenborg, M., Riaz, S. P., Lim, E., Page, R., Baldwin, D. R., Jakobsen, E., Vedsted, P., Lind, M., Peake, M. D., Mellemgaard, A., Spicer, J., Lang-Lazdunski, L., & Møller, H. (2014). Survival of patients with small cell lung cancer undergoing lung resection in England, 1998–2009. Thorax, 69(3), 269-273. https://doi.org/10.1136/thoraxjnl-2013-203884

Introduction: Chemotherapy or chemoradiotherapy is the recommended treatment for small cell lung cancer (SCLC), except in stage I disease where clinical guidelines state there may be a role for surgery based on favourable outcomes in case series. Evi... Read More about Survival of patients with small cell lung cancer undergoing lung resection in England, 1998–2009.

High procedure volume is strongly associated with improved survival after lung cancer surgery (2013)
Journal Article
Lüchtenborg, M., Riaz, S. P., Coupland, V. H., Lim, E., Jakobsen, E., Krasnik, M., Page, R., Lind, M. J., Peake, M. D., & Møller, H. (2013). High procedure volume is strongly associated with improved survival after lung cancer surgery. Journal of Clinical Oncology, 31(25), 3141-3146. https://doi.org/10.1200/JCO.2013.49.0219

Purpose
Studies have reported an association between hospital volume and survival for non–small-cell lung cancer (NSCLC). We explored this association in England, accounting for case mix and propensity to resect.

Methods
We analyzed data on 134,293... Read More about High procedure volume is strongly associated with improved survival after lung cancer surgery.

Proteomic (antibody microarray) exploration of the molecular mechanism of action of the specific COX-2 inhibitor DuP 697 (2013)
Journal Article
Agarwal, V., Hodgkinson, V. C., Eagle, G. L., Scaife, L., Lind, M. J., & Cawkwell, L. (2013). Proteomic (antibody microarray) exploration of the molecular mechanism of action of the specific COX-2 inhibitor DuP 697. International Journal of Oncology, 42(3), 1088-1092. https://doi.org/10.3892/ijo.2013.1784

We have previously shown that specific COX-2 inhibitors, including DuP 697, have anti-proliferative effects on mesothelioma cells and potentiate the cytotoxicity of pemetrexed. Here, we used a novel proteomic approach to explore the mechanism of acti... Read More about Proteomic (antibody microarray) exploration of the molecular mechanism of action of the specific COX-2 inhibitor DuP 697.

PTEN protein expression in malignant pleural mesothelioma (2012)
Journal Article
Agarwal, V., Campbell, A., Beaumont, K. L., Cawkwell, L., & Lind, M. J. (2013). PTEN protein expression in malignant pleural mesothelioma. Tumor Biology, 34(2), 847-851. https://doi.org/10.1007/s13277-012-0615-9

Malignant pleural mesothelioma is associated with poor prognosis and despite recent advances in chemotherapy, the median survival is still approximately 12 months. Loss of phosphatase and tensin homolog (PTEN) protein expression may lead to constitut... Read More about PTEN protein expression in malignant pleural mesothelioma.

Proteomic identification of putative biomarkers of radiotherapy resistance (2012)
Thesis
Scaife, L. (2012). Proteomic identification of putative biomarkers of radiotherapy resistance. (Thesis). University of Hull. Retrieved from https://hull-repository.worktribe.com/output/4214086

Background
Currently, tumour response to radiotherapy cannot be predicted meaning that those patients with tumours resistant to the therapy endure the harmful side effects associated with ionising radiation in the absence of therapeutic gain. The ai... Read More about Proteomic identification of putative biomarkers of radiotherapy resistance.

Proteomic identification and validation of biomarkers associated with resistance to radiotherapy in breast cancer (2012)
Thesis
ElFadl, D. (2012). Proteomic identification and validation of biomarkers associated with resistance to radiotherapy in breast cancer. (Thesis). University of Hull. Retrieved from https://hull-repository.worktribe.com/output/4218629

Background:
Breast cancer is an important health issue. The majority of patients present with early stage cancer and are therefore candidates for breast conserving surgery and radiotherapy. A proportion will suffer from local recurrence, which may b... Read More about Proteomic identification and validation of biomarkers associated with resistance to radiotherapy in breast cancer.

Pilot and feasibility study: comparative proteomic analysis by 2-DE MALDI TOF/TOF MS reveals 14-3-3 proteins as putative biomarkers of response to neoadjuvant chemotherapy in ER-positive breast cancer (2012)
Journal Article
Hodgkinson, V. C., Agarwal, V., ElFadl, D., Fox, J. N., McManus, P. L., Mahapatra, T. K., Kneeshaw, P. J., Drew, P. J., Lind, M., & Cawkwell, L. (2012). Pilot and feasibility study: comparative proteomic analysis by 2-DE MALDI TOF/TOF MS reveals 14-3-3 proteins as putative biomarkers of response to neoadjuvant chemotherapy in ER-positive breast cancer. Journal of Proteomics, 75(9), 2745-2752. https://doi.org/10.1016/j.jprot.2012.03.049

Neoadjuvant chemotherapy is used to treat oestrogen receptor-positive breast cancer however chemo-resistance is a major obstacle in this molecular subtype. The ability to predict tumour response would allow chemotherapy administration to be directed... Read More about Pilot and feasibility study: comparative proteomic analysis by 2-DE MALDI TOF/TOF MS reveals 14-3-3 proteins as putative biomarkers of response to neoadjuvant chemotherapy in ER-positive breast cancer.

The significance of the EGFR pathway in malignant pleural mesothelioma (2012)
Thesis
Agarwal, V. (. (2012). The significance of the EGFR pathway in malignant pleural mesothelioma. (Thesis). Hull York Medical School, the University of Hull and the University of York. Retrieved from https://hull-repository.worktribe.com/output/4214047

Introduction
EGFR, MTOR and COX2 are up regulated in malignant pleural mesothelioma (MPM). In this study we aimed to determine the expression of Lipoxygenase enzymes (LOX), absence of PTEN protein expression and the cytotoxic effect of EGFR, MTOR an... Read More about The significance of the EGFR pathway in malignant pleural mesothelioma.

Proteomic identification of predictive biomarkers of resistance to neoadjuvant chemotherapy in luminal breast cancer: a possible role for 14-3-3 theta/tau and tBID? (2012)
Journal Article
Hodgkinson, V. C., ELFadl, D., Agarwal, V., Garimella, V., Russell, C., Long, E. D., Fox, J. N., McManus, P. L., Mahapatra, T. K., Kneeshaw, P. J., Drew, P. J., Lind, M. J., & Cawkwell, L. (2012). Proteomic identification of predictive biomarkers of resistance to neoadjuvant chemotherapy in luminal breast cancer: a possible role for 14-3-3 theta/tau and tBID?. Journal of Proteomics, 75(4), 1276-1283. https://doi.org/10.1016/j.jprot.2011.11.005

Introduction: Chemotherapy resistance is a major obstacle in effective neoadjuvant treatment for estrogen receptor-positive breast cancer. The ability to predict tumour response would allow chemotherapy administration to be directed towards only thos... Read More about Proteomic identification of predictive biomarkers of resistance to neoadjuvant chemotherapy in luminal breast cancer: a possible role for 14-3-3 theta/tau and tBID?.

The identification of biomarkers of chemotherapy resistance in breast cancer using comparative proteomics (2011)
Thesis
Hodgkinson, V. C. (2011). The identification of biomarkers of chemotherapy resistance in breast cancer using comparative proteomics. (Thesis). University of Hull. Retrieved from https://hull-repository.worktribe.com/output/4211852

Background:Chemotherapy resistance is a major obstacle in effective neoadjuvant treatment for locally advanced breast cancer. The ability to predict tumour response would allow chemotherapy administration to be directed towards only those patients wh... Read More about The identification of biomarkers of chemotherapy resistance in breast cancer using comparative proteomics.

Differential proteomics in the search for biomarkers of radiotherapy resistance (2011)
Journal Article
Scaife, L., Hodgkinson, V. C., Drew, P. J., Lind, M. J., & Cawkwell, L. (2011). Differential proteomics in the search for biomarkers of radiotherapy resistance. Expert Review of Proteomics, 8(4), 535-552. https://doi.org/10.1586/EPR.11.32

The individualization of radiotherapy treatment would be beneficial for cancer patients; however, there are no predictive biomarkers of radiotherapy resistance in routine clinical use. This article describes the body of work in this field where compa... Read More about Differential proteomics in the search for biomarkers of radiotherapy resistance.

A pilot study to investigate the role of the 26S proteasome in radiotherapy resistance and loco-regional recurrence following breast conserving therapy for early breast cancer (2011)
Journal Article
ELFadl, D., Hodgkinson, V. C., Long, E. D., Scaife, L., Drew, P. J., Lind, M. J., & Cawkwell, L. (2011). A pilot study to investigate the role of the 26S proteasome in radiotherapy resistance and loco-regional recurrence following breast conserving therapy for early breast cancer. The Breast : official journal of the European Society of Mastology, 20(4), 334-337. https://doi.org/10.1016/j.breast.2011.02.017

Breast conserving therapy is a currently accepted method for managing patients with early stage breast cancer. However, approximately 7% of patients may develop loco-regional tumour recurrence within 5 years. We previously reported that expression of... Read More about A pilot study to investigate the role of the 26S proteasome in radiotherapy resistance and loco-regional recurrence following breast conserving therapy for early breast cancer.